Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.

Daneng Li, MD, evaluates the use of cabozantinib plus atezolizumab in first-line advanced unresectable HCC as seen in the COSMIC-312 study.

Dr Daneng Li reviews updated safety and efficacy results of durvalumab plus tremelimumab from the phase 3 HIMALAYA study in frontline unresectable HCC.

Nicole Rich, MD, reviews the patient selection for atezolizumab-bevacizumab and discusses patients in whom this regimen is contraindicated in the frontline setting in advanced HCC.

Pierre Gholam, MD, considers the optimal treatment selection for patients in whom an atezolizumab-bevacizumab combination isn’t a suitable frontline therapeutic option.

Experts in gastrointestinal cancers, Drs Pierre Gholam and Daneng Li, comment on the role of single-agent immunotherapy for first-line treatment of advanced HCC.

Daneng Li, MD, discusses novel regimens in the pipeline being evaluated for the treatment of frontline advanced HCC.

An expert gastroenterologist, Dr Pierre Gholam, discusses the phase 3 LAUNCH trial and shares insight on the potential role of liver-directed therapy in the treatment of advanced hepatocellular carcinoma.

Anthony B. El-Khoueiry, MD, reviews anti-angiogenic systemic therapy options for patients with advanced HCC in the second-line and beyond setting.

Pierre Gholam, MD, comments on systemic immunotherapy options for second-line and beyond treatment of advanced hepatocellular carcinoma.

Experts in gastrointestinal cancers share factors to consider when selecting the optimal second-line therapy for patients with advanced hepatocellular carcinoma.

Experts in gastrointestinal cancers comment on their treatment approaches for patients with second-line advanced hepatocellular carcinoma who receive frontline TKI therapy.

Key opinion leaders in gastrointestinal cancers provide insight on unmet needs and challenges in the treatment of advanced hepatocellular carcinoma in the second-line and beyond setting.

Dr Nicole Rich discusses immunotherapy and potential combinations in intermediate and advanced hepatocellular carcinoma.

Drs Anthony B. El-Khoueiry, Daneng Li, Nicole Rich, and Pierre Gholam share treatment approaches for a 63-year-old woman who received an advanced HCC diagnosis with Child-Pugh A liver function.